European Hematology Association 2021 Virtual Congress (EHA 2021)

Virtual 09 June 2021 - 17 June 2021

Fixed-duration first-line ibrutinib-venetoclax improves PFS over chlorambucil-obinutuzumab for CLL

11 Aug 2021 by

Fixed-duration ibrutinib plus venetoclax (I+V) significantly improved progression-free survival (PFS) over chlorambucil plus obinutuzumab (Clb+O) in the first-line treatment of patients with chronic lymphocytic leukaemia (CLL), primary results of the phase III GLOW trial showed.

Fixed-duration first-line ibrutinib-venetoclax improves PFS over chlorambucil-obinutuzumab for CLL

11 Aug 2021

Voxelotor improves Hb levels, haemolysis markers in younger children with SCD

28 Jul 2021 by

The use of voxelotor weight-based dosing equivalent to 1,500 mg appears to increase haemoglobin (Hb) levels and decrease clinical markers of haemolysis in patients aged 4–11 years with sickle cell disease (SCD), according to a study presented at EHA 2021.

Voxelotor improves Hb levels, haemolysis markers in younger children with SCD

28 Jul 2021

Luspatercept scores in nontransfusion-dependent β-thalassemia

26 Jul 2021 by

The first-in-class erythroid maturation agent, luspatercept, improved anaemia in adults with nontransfusion-dependent β-thalassemia (NTDT) in the phase II BEYOND study reported at EHA 2021.

Luspatercept scores in nontransfusion-dependent β-thalassemia

26 Jul 2021

Zanubrutinib demos improved response over ibrutinib in R/R CLL/SLL

20 Jul 2021 by

Patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) may have a greater response to zanubrutinib than ibrutinib as well as better progression-free survival (PFS), according to the first interim analysis results of the ALPINE trial.

Zanubrutinib demos improved response over ibrutinib in R/R CLL/SLL

20 Jul 2021

Mitapivat shows potential for PK deficiency

12 Jul 2021 by

Mitapivat, an investigational, first-in-class, oral, allosteric pyruvate kinase R (PKR) activator, had clinically meaningful benefit for individuals with PK deficiency regardless of transfusion status, according to the phase III ACTIVATE trials presented at EHA 2021.

Mitapivat shows potential for PK deficiency

12 Jul 2021

D-Rd triumphs over Rd as first-line treatment for transplant-ineligible NDMM

07 Jul 2021 by

Results from the phase III MAIA study showed that the triplet regimen of daratumumab, lenalidomide, and dexamethasone (D-Rd) improved overall survival (OS) compared with lenalidomide plus dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

D-Rd triumphs over Rd as first-line treatment for transplant-ineligible NDMM

07 Jul 2021

Isatuximab-Kd shows consistent efficacy across RMM patient subgroups

07 Jul 2021 by

Findings from subgroup analyses of the IKEMA trial presented at EHA 2021 aligned with those observed in the overall analysis, further validating the benefits of the isatuximab + carfilzomib-dexamethasone (Isa-Kd) combination regimen for relapsed multiple myeloma (RMM).

Isatuximab-Kd shows consistent efficacy across RMM patient subgroups

07 Jul 2021

5-year ECHELON-1 updates show durable benefits of brentuximab vedotin-chemo for cHL

05 Jul 2021 by

In the 5-year updated results of the phase III ECHELON-1 study presented at EHA 2021, a combination of the CD30-directed ADC* brentuximab vedotin and chemotherapy (CT) continued to show potential for individuals with previously untreated stage III/IV classical Hodgkin lymphoma (cHL).

5-year ECHELON-1 updates show durable benefits of brentuximab vedotin-chemo for cHL

05 Jul 2021

Lymphoma patients at high risk of long COVID-19

03 Jul 2021 by

Patients with B-cell non-Hodgkin lymphoma hospitalized for COVID-19 are at an increased risk of developing persistent COVID-19 and death, according to a retrospective study presented at EHA 2021.

Lymphoma patients at high risk of long COVID-19

03 Jul 2021

Acalabrutinib maintains efficacy over 4 years in treatment-naïve CLL

30 Jun 2021 by

Acalabrutinib with or without obinutuzumab maintains significant progression-free survival (PFS) benefit over the chemoimmunotherapy combination of obinutuzumab plus chlorambucil (O + Clb) through 4 years in treatment-naïve chronic lymphocytic leukaemia (CLL) patients, according to the phase III ELEVATE-TN study presented at EHA 2021.

Acalabrutinib maintains efficacy over 4 years in treatment-naïve CLL

30 Jun 2021